2024.04.25
Pangyo, South Korea 9:00-17:30(GMT+9)
Hanoi, Vietnam 9:00-17:30(GMT+7)
COUNTDOWN to ODC24
00
Days
:
00
Hours
:
00
Minutes
:
00
Seconds
Information
General registration Benefits
Pre-registration Benefits
Pre-registration has ended
Pre-registration benefits may be partially changed or excluded depending on the organizer's circumstances and may close early due to limited quantities.
On-site registrants cannot receive pre-registration benefits.
Speaker
Session 01 Organoids Unleashed : Closer to Artificial Organs
Chair: Inbo Han M.D., Ph.D. Professor, CHA University, CHA Bundang Medical Center, Neurosurgery, Republic of Korea
This session will specifically focus on the application of organoids in regenerative medicine and potentially in artificial organs. It will delve into how organoid technology is creating new possibilities in these areas, particularly in organ repair and replacement. The session will discuss the latest advancements in developing complex organoid structures, address ethical considerations, and explore how commercialization might help solve organ shortages.
Robert Coppes Ph.D.
Professor, University Medical Center Groningen
The Netherlands
Research field
Organoids for Post-Radiotherapy Regeneration of Salivary Glands, the RESTART study
He focuses on researching radiation-induced damage in salivary glands and the development of salivary gland organoids for regenerative medicine, particularly aiming to mitigate the side effects of cancer therapies. His work is significant in understanding and improving cancer treatment outcomes while preserving normal tissue function.
Ryuichi Okamoto M.D., Ph.D.
Professor, Tokyo Medical and Dental University (TMDU)
Japan
Research field
Clinical Application of Patient-Derived Organoids
A prominent researcher in the field of gastroenterology and hepatology, has made significant contributions to the development of organoid-based regenerative medicine, particularly for treating ulcerative colitis. He is noted for his pioneering work in culturing organoids from healthy regions of a patient's own intestine and re-transplanting them into diseased areas to regenerate tissue.
Related link
Xiling Shen Ph.D.
CSO, Terasaki Institute/ CPRIT Professor, MD, Anderson Cancer Center
United States of America
Research field
Patient-Derived Micro-Organospheres Enable Precision Oncology
He is a distinguished figure in the field of precision medicine, is recognized for his leadership in various significant consortia. He has made notable contributions in systems biology, particularly in areas like cancer, stem cells, the gut-brain axis, and the microbiome. Notably, he founded Xilis, Inc., a startup that raised $89M in Series-A financing and has been acknowledged as a top life science startup, focusing on patient-derived models of cancer.
KyungJin Lee Ph.D.
CTO, ORGANOIDSCIENCES
Republic of Korea
Research field
Current Standing and Future Perspectives of Organoid Regenerative Medicine
He is at the forefront of organoid technology innovation in the biotech industry. He is leading the development of organoid technology and focusing on regulatory requirements related to development, manufacturing, CMC, quality, and non-clinical facets of organoid-based regenerative medicinedevelopment, providing vital scientific expertise across multiple stages and applications of organoid technology
Session 02 Unveiling the Future of Science : Innovation Tech
Chair: Bon-Kyoung Koo Ph.D. Director, Institute for Basic Science, Republic of Korea
This session will specifically focus on the application of organoids in regenerative medicine and potentially in artificial organs. It will delve into how organoid technology is creating new possibilities in these areas, particularly in organ repair and replacement. The session will discuss the latest advancements in developing complex organoid structures, address ethical considerations, and explore how commercialization might help solve organ shortages.
Ramanuj DasGupta Ph.D.
Senior Group Leader, Genome Institute of Singapore / A*STAR
Singapore
Research field
A Phenotype-Driven Precision Oncology Platform or Target and Biomarker Discovery
He leads research on patient-specific treatment paradigms using advanced genomic technologies. His focus includes developing novel precision oncology platforms, studying tumor heterogeneity, and identifying new therapeutic targets and biomarkers in solid cancers.
Jun Wu Ph.D.
Associate Professor, UT Southwestern,
Department of Molecular Biology
United States of America
Research field
Integrated Stem Cell based Embryo Models for Early Human Development
Dr. Wu’s work has contributed to the generation of new stem cells for basic and translational studies, and developing novel and efficient genome and epigenome editing tools. Dr. Wu has also generated PSC-derived interspecies chimeras and developed an efficient and versatile interspecies blastocyst complementation system for the generation of organs and tissues from one species inside another species.
Lena Smirnova Ph.D.
Assistant Professor, Johns Hopkins University
United States of America
Research field
Brain Microphysiology Systems: Increasing Complexity to Increase Functionality
Dr. Smirnova’s focus is to develop new, predictive, and human-relevant in vitro methods in developmental neurotoxicology, such as iPSC-derived brain oroganoids. Her primary research interest is molecular mechanisms of cellular responses to environmental stress. Her main interest over the last few years was the role of miRNA in neurodevelopment and neurotoxicity, and identification whether miRNA constitute an interface of gene-environmental interactions that contribute to autism.
YongKeun Park Ph.D.
Professor, KAIST/ CEO, Tomocube, Inc.
Republic of Korea
Kunyoo Shin Ph.D.
Associate Professor, Seoul National University
Republic of Korea
Research field
Advancing Developmental Biology and Companion Diagnosis Exploiting Holotomography: High-Resolution, Label-Free 3D Imaging of Live Organoids
YongKeun (Paul) Park, CTO at Tomocube, is instrumental in advancing holotomography, driving live-cell imaging towards 4D label-free techniques and organoid research. His pioneering work, central to Tomocube’s innovation, offers profound insights for biotech research and clinical applications, enhancing the understanding of cellular dynamics in their natural state.
Research field
Human Assembloids to Study the Dynamic Cellular Interplay in Human Diseases
He is interested in the signaling networks that operate in stem cell regulation during tissue homeostasis and regeneration, and in various diseases including cancers. Particularly, his lab is interested in understanding how such signaling networks exert their effects in the maintenance of tissue integrity and tumor initiation/growth through the regulation of tissue stem cell physiology.
Session 03 Respecting Life : Animal-free Solution
Chair: Il-Ung Oh Ph.D. Director, Ministry of Food and Drug Safety, Republic of Korea
In this session, we examine the efforts to replace the use of animals and animal-derived ingredients in our surroundings. We will explore topics such as cultured meat / alternative protein in the food industry, as well as efforts to replace animal testing in fields such as cosmetics, chemicals, and pharmaceuticals.
Borami Seo
Director of Government, Affairs,
Humane Society International Korea
Republic of Korea
Won-Jeoung Park
Ethics Director, Lush Korea
Republic of Korea
Sudeep Joshi Ph.D.
Postdoctoral Research Scientist,
The Francis Crick Institute and
King’s College,London
United Kingdom
Research field
The Power of Building Together for Cutting-Edge Science
She is Director of Government Affairs for Humane Society International/Korea. After receiving a Bachelor of Science in Animal Behaviour at the University of Sheffield and a higher education certificate in the Development Study at the University of London, she worked at a London-based NGO as a researcher to support producing lobbying materials for advocacy campaigns and at a Seoul-based NGO as a Policy Manager. Since joining HSI in 2015, she has led multiple successful legislative reform efforts, including amendments to chemical legislations, prioritising alternatives to animal approaches for safety assessment. She has held policy advisory roles for Ministry-led projects and gave numerous talks at academic conferences to promote interdisciplinary approaches for humane science.
Research field
The End Of Animal Testing Is In Sight
Since she has been interested in curating cases of game changers and value-led change makers to make a world the better place, most of her work experience was creating initiatives for fundamental problem-solving for a sustainable business. Currently, she works for Lush Korea as the Ethics Director who supports ethical campaigns embodying the brand's beliefs and a business roadmap for leaving the world Lusher than we found it. Especially, her notable contribution is running a campaign for fighting against animal testing and promoting alternative methods through coordinating Lush Prize, the world most famed and largest animal-free testing award.
Research field
A Robotic Process Automation System for Biomanufacturing Animal-Free in-vitro 3D Tissue and Organoid Models for Drug Screening
Dr. Sudeep Joshi is a scientist at The Francis Crick Institute and King’s College London who was awarded £10k for his work of physical ‘printing’ (also called ‘3D bioprinting) of human tissues to be used in safety testing of drugs and other chemicals, instead of animals.
Dr. Sudeep Joshi’s main focus is on interdisciplinary research, modelling 3D cell culture systems, stem cells, and tissue engineering techniques, with a strong interest in new technology development.
Sanghee Park Ph.D.
CEO, Chemtopia Co., Ltd
Republic of Korea
Hyo-Jung Yoon Ph.D.
Head of Application Tech, TN,
CJ CheilJedang Bio
Republic of Korea
André Gerth Ph.D.
CEO, Lambda Biologics GmbH
Germany
Research field
Regulatory Approach of Non-Animal Testing Methos, QSAR, Read-across and etc. in Korea
Park Sang-hee, CEO of Chemtopia, graduated from the Department of Chemistry at Ewha Womans University in 1994. He went on to earn a master's degree in physics from the same graduate school and a doctorate in public health from Yonsei University. Sang-hee served as a chemical registration reviewer for the National Institute of Environmental Research and established Chemtopia in 2002. Initially, when founded in 2002, the company primarily focused on regulations such as hazard assessment of chemical substances like humidifier disinfectants. However, in recent years, the company has expanded its business scope under the principles of environment, responsibility, and transparent management (ESG). Chemtopia now offers consulting services to companies on various chemicals and safety, based on ESG management.
Research field
The Science of Alternative Proteins
Dr. HY Yoon is a distinguished scientist and seasoned industry professional with
a rich and diverse background in food science and technology. She began her
career at Sara Lee (Hillshire Brands), where she contributed to product
development, emerging technologies, and food safety-science innovation. Since
then she has had increased leadership roles across many global companies.
Dr. Yoon's executive roles involve Product Development, Science & Technology and Food Ingredient Research at CJ CheilJedang, a leading global food & bio company in Korea.
Dr. Yoon led efforts to integrate cutting-edge technologies such as alternative proteins into the company's food business. With over 15+ years of result-driven experience, she continues to drive innovation and excellence, focusing on specialized areas such as emerging alternative protein solutions.
Research field
The New Era of Animal Free Solution with Lambda Biologics
Dr. Gerth, CEO of Lambda Biologics, has over 20 years of combined experience in the use of stem cells for treatment of various diseases, and managing cord blood companies. On top of this, Dr. Gerth has successfully led more than 10 global M&As, and plans to lead the growth of Lambda Biologics based on his extensive background and capabilities.
Session 04 From Lab to Life : Real-World Innovations
Chair: Mi-Young Son Ph.D. Director, Korea Research Institute of Bioscience and Biotechnology/ Stem Cell Convergence Research Center, Republic of Korea
This session will concentrate on real-world examples where organoids have been successfully utilized in development and research. It will cover case studies demonstrating the practical application of organoids in drug testing, disease modeling, and personalized medicine. The focus will be on showcasing how organoids have bridged the gap between laboratory research and tangible, impactful solutions in various domains of healthcare and scientific research.
Seoyeon Kyung
Senior researcher, COSMAX BTI
Republic of Korea
Hyung-Joon PARK Ph.D.
CTO, Grassmedi
Republic of Korea
Jongsuk Chung Ph.D.
R&D director, Gencurix Inc.
Republic of Korea
Research field
Evaluating Anti-Hair Loss Efficacies Using Scalp and Hair Follicle Mimic Organoids
Seoyeon Kyung is currently a PhD student at center for digital health, medical science research institute of KyungHee University. She received bachelor’s and master’s degree in food and nutrition from Yonsei University. Additionally, she has been working as a senior researcher at COSMAX BTI since 2017. From 2017 to 2023, she presented four poster presentations and one oral presentation at the international academic conference IFSCC. Additionally, she has been taking a leading role in hair loss and hair research at COSMAX BTI. Since 2022, she has developed a deep interest in integrating organoids into dermatology and have been conducting research in this area.
Research field
Organoid Technology in Veterinary Medicine and the Pet Industry
Hyung-Joon Park, Ph.D., is the Director of Research at Grassmedi, a leading company dedicated to the development and commercialization of innovative animal healthcare products. He brings a wealth of experience and expertise to his role, leading research and development initiatives in various fields, including Biotechnology, Biomaterials, Nano/micro technology, Drug delivery system, Genetic engineering, Tissue engineering.
He majored in Biomedical Engineering at Korea University and received his Ph.D. in Biomedical Engineering from the Department of Interdisciplinary Bio/Micro System Technology, College of Engineering, Korea University.
Dr. Park's current research at Grassmedi focuses on developing innovative solutions for animal health, including:
- Customized extended-release targeted drug delivery systems for animals
- Atopic dermatitis treatment for companion animals
- Dysbiosis diagnosis and treatment based on feline gut microbiome analysis
Research field
Method for the Genomic Characterization of Organoids from Tumor Tissue using next Generation Sequencing
Jongsuk Chung has an extensive background in research and development within the field of in vitro diagnostics (IVD) and companion diagnostics. His career spans over fourteen years at Samsung Electronics, where he focused on developing IVD products utilizing emerging technologies such as microarray and real-time PCR. During his tenure, he contributed significantly to the development and commercialization of various diagnostic products, including genotyping microarrays for hereditary diabetes, infectious disease screening microarrays, and lung cancer SNP microarrays utilizing photolithography technology.
Currently, he serves as the Director of Research and Development at Gencurix, a company specializing in IVD and companion diagnostics based on digital PCR and NGS technologies. His expertise and contributions have significantly impacted the advancement and standardization of diagnostictechnologies in both clinical and research settings.
Siyoung Lee Ph.D.
Team Leader, Geninus, Inc.
Republic of Korea
Brett J. Kagan Ph.D.
CSO, Cortical Labs
Australia
Research field
Advances in Genome Analysis Technology from Single cell Analysis to Spatial Transcriptome Analysis
Siyoung Lee is an professional involved in the advancement of single cell RNA-sequencing technologies. With a keen focus on planning new business models, he has spearheaded initiatives related to single cell RNA-sequencing, including the establishment of marketing strategies and the development of cutting-edge drug development platforms. Notably, he was leading a national project aimed at leveraging single cell RNA-sequencing to combat COVID-19, showcasing their commitment to driving impactful advancements at both the national and global levels. He was a dedicated researcher at the forefront of functional genomics and phytochemical studies. With a primary focus on advancing targeted therapies for Inflammatory Bowel Diseases (IBD), he conducts in-depth functional studies of target genes aimed at developing effective treatment strategies. Additionally, he has led projects involving the design and execution of experiments related to phytochemical studies, demonstrating his versatility and expertise across various research domains. Through [his/her] innovative approach and commitment to scientific excellence, he is contributing significantly to the advancement of medical research and the development of novel therapeutic interventions.
Research field
Can we Harness Intelligence from Neural Organoids? Opportunities
and Challenges
Dr Brett J. Kagan is the Chief Scientific Officer at Cortical Labs. Cortical Labs is a multidisciplinary deep-tech startup looking at integrating hardware, software, and synthetic biology approaches to explore how to harness intelligence from neurons on a chip. Dr Kagan has a PhD in neuroscience focusing on stem cell therapy along and completed post-doctoral work in bioinformatics and regenerative medicine. Recent work includes developing the first real-time closed-loop demonstration of in-vitro intelligence in a simplified pong-game environment, along with working to better test and understand these systems, including exploring ethical approaches to the development and use of these systems.
Yong Kyun Kim M.D., Ph.D.
MD, Catholic University of Korea, College of Medicine/ CEO, Rgenorgano biotgechnology
Republic of Korea
Hyang-Ae Lee Ph.D.
Principal researcher, Korea Institute of Toxicology
Republic of Korea
HongSeok Choi Ph.D.
Principal Researcher, Abion Inc.
Republic of Korea
Research field
Applications of Human iPSCs-derived Organoids in Practice: Present and Future Perspectives
I graduated from Catholic University of Medicine in 1997 and am currently a professor of nephrology at St. Vincent’s Hospital of Catholic University of Medicine and the director of the Cell Death Disease Research Center at Catholic University of Medicine. My main research interest is developing treatments for kidney diseases using kidney organoids. We have published papers for the generation of advanced kidney organoids and its applications.
Based on basic research results, we are working hard and consistently with our research institute members to create treatments that can be applied clinically.
Research field
Development of Human Cardiac Organoids for Preclinical Studies
Since 2007, Dr. Lee has worked at the Korea Institute of Toxicology (KIT), the government-funded non-clinical research institution in Korea. In the early stages of her career, she served for several years as a study director for cardiac toxicity studies at KIT, ensuring compliance with GLP standards. Currently, as a Principal Investigator in the Department of Predictive Toxicology, she is focused on developing alternative animal testing methods using cardiac organoid-based non-clinical testing platforms and conducting standardization research for organoid platforms. With her educational background in electrophysiology, she has extensive experience leading numerous projects on the development of human stem cell-based organoids and stem cell-based alternatives to animal testing.
Research field
Efficacy Test for Biologics Against Respiratory Viruses in Human Lung Organoid
Hong Seok Choi received his PhD in Microbiology and Immunology at the University of Florida in 2014. During his PhD, he studied the oncogenesis, lytic reactivation, and latency of Kaposi’s sarcoma herpesvirus (KSHV). Hong Seok Choi did his post-doctoral trainings at NCI/NIH in the United States, responsible for the research of KSHV infection in hypoxic environment; and at DVP/FDA, responsible for the study of broad-spectrum influenza vaccine. Then, he joined Abion Inc. in 2020, to develop.
Junsung Kim
Technical Sales Specialist, Thermo Fisher Scientific Korea
Republic of Korea
Research field
Accelerating 3D Organoid research using CellInsight CX7 Laser Pro, high-content screening technologies
Junsung Kim was awarded a master’s degree in Bioengineering at the Korea University.
He had worked as a researcher in the Korea Animal Health Product (KAHPA) and developed his career as a laser microscope specialist in Evident (Prev. Olympus) Korea over 8 years.
He currently works at Thermo Fisher Scientific as a technical sales specialist of cell analysis imaging system, especially High-content screening instrument.
Based on his imaging research field experience, he always serves advanced technical support to customer.
Research field
3D Biology and The Paradigm Shift in Next Generation Drug Discovery
Minho, he got his PhD in Neuroscience & Electro Physiology at the Seoul National University. He is the Senior Application Scientist of Molecular Devices and responsible to provide technical talk to spread out Molecular Devices technology through training inner and outer customer to give them a better understanding about Molecular Devices solutions and is covering all Asia Pacific region including Japan, India, SEA and ANZ
Program
Organizer
Sponsors
